Calculate Your Salary Ranking
Home > Amicus Therapeutics Salary

Amicus Therapeutics Salary
  • 76
  • 21
  • 93

Amicus Therapeutics average salary is $171,847, median salary is $210,000 with a salary range from $90,000 to $215,539.
Amicus Therapeutics salaries are collected from government agencies and companies. Each salary is associated with a real job position. Amicus Therapeutics salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 3 Amicus Therapeutics Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More Info
General 90,000-90,000 Cranbury, NJ, 08512 2012 Amicus Therapeutics General Salaries (1)
Amicus Therapeutics Cranbury, NJ Salaries
All Other, Physicians & Surgeons 215,539-215,539 Cranbury, NJ, 08512 2011 Amicus Therapeutics All Other, Physicians & Surgeons Salaries (1)
Amicus Therapeutics Cranbury, NJ Salaries
Clinical Research, Medical Director 210,000-210,000 Cranbury, NJ, 08512 2010 Amicus Therapeutics Clinical Research, Medical Director Salaries (1)
Amicus Therapeutics Cranbury, NJ Salaries
Amicus Therapeutics Jobs
See more Amicus The Jobs »
Calculate how much you could earn

It's FREE. Based on your input and our analysis.    How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address
Recent Amicus Therapeutics Salaries (March 1, 2017)
Assistant Professor University of Oklahoma $42,860 Norman, OK, 73019 01/05/2015
General OMRON $65,998 Houston, TX, 77001 09/07/2015

Amicus Therapeutics salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Amicus Therapeutics Information
  • Amicus Therapeutics
  • Industry: BioTech/Drugs
  • City: Cranbury, NJ
  • Amicus was established in April 2002 with seed financing provided by CHL Medical Partners II, a venture capital fund managed by Collinson, Howe & Lennox, and is focused on the development of orally-active, small molecule drugs capable of restoring normal function to mutant proteins. Amicus was founded to capitalize on the discovery that many diseases of genetic origin are caused by missense mutations and other rescuable mutations that result in the misfolding of a protein/enzyme. These misfolded mutant proteins become targeted for degradation before reaching their normal site of action, leading to the disease phenotype. Pharmacological Chaperones are designed to